Origin Energy Limited (OGFGF) Receives a New Rating from Jefferies
In a report released today, Amit Kanwatia from Jefferies initiated coverage with a Buy rating on Origin Energy Limited (OGFGF – Research Report) and a price target of A$12.05. The company's shares closed last Wednesday at $7.10.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Kanwatia is ranked #6755 out of 9596 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Origin Energy Limited with a $6.82 average price target.
Based on Origin Energy Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $8.8 billion and a net profit of $1.02 billion. In comparison, last year the company earned a revenue of $7.93 billion and had a net profit of $995 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Adobe Stock Slumps as Results Leave Some Waiting for More Signs of AI Success
Adobe shares slumped Friday, as the design software developer failed to impress with its quarterly results, despite topping Wall Street estimates. Several Wall Street analysts indicated Adobe's results didn't suggest enough progress with its own AI offerings to ease worries it could be held back by growing competition and AI disruption. Deutsche Bank said it expects the stock 'to remain range-bound until the company demonstrates more tangible success from AI."Adobe (ADBE) shares slumped Friday, as the design software developer failed to impress with its quarterly results, despite topping Wall Street estimates and boosting its full-year outlook. The stock led S&P 500 decliners by sinking nearly 6% in recent trading to roughly $390, leaving shares down 12% for 2025. "The key investor question remains when (if) AI innovation can move the needle," wrote Morgan Stanley analysts, who added the quarter "brought little to quell the bear concern around AI contribution being unable to reaccelerate growth while bulls must remain patient for encouraging AI metrics to move the needle." Still, the analysts said they are "overweight" on the stock with a $510 target, expecting Adobe AI monetization to ramp up in the next fiscal year. Jefferies analysts, who reiterated a "buy" rating and $590 price target on Adobe's potential growth driven by its AI offerings, echoed the comments, writing that while the firm's earnings showed some AI progress, it was "maybe not enough to appease bears." Jefferies also noted that Adobe's forecast, while higher, would imply a slowdown in growth in the fiscal fourth quarter, though they added they believe it "reflects management's conservatism amid ongoing macro uncertainties." Bank of America, which raised its target to $475 from $424 on Adobe's outlook and AI growth potential, said the company demonstrated "solid execution in a weaker software backdrop," calling it a "break from this reporting season, with most software companies opting not to flow through upside to the full year." Citi analysts, however, were less convinced, citing worries growing competition and AI disruption could hold Adobe back. Citi issued a "neutral" rating for the stock and $465 target. Deutsche Bank analysts, who affirmed their "hold" rating and $475 target, said they "expect the stock to remain range-bound until the company demonstrates more tangible success from AI." Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch
Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, with an unchanged 'Buy' rating. This was after the successful launch of the COPD treatment Ohtuvayre, which has witnessed strong sales growth. During the first quarter, Ohtuvayre delivered $71 million in sales, reflecting an increase of nearly 90% from the previously reported 37 million in the last quarter. Verona Pharma plc (NASDAQ:VRNA) continues to capitalize on this growing demand, with peak sales projections between $3 billion and $5 billion. As the numbers suggest, this is anything but ordinary. The optimism surrounding the company's profitability in the second quarter is just the cherry on top. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Some believe that Verona Pharma plc (NASDAQ:VRNA) is heading north to be the next big franchise. With its potential, Wall Street anticipates the giant to achieve $1 billion in sales by 2028, driven by its safety profile, global expansion, robust patent protection, and an underserved market of 398 million people with COPD. Verona Pharma plc (NASDAQ:VRNA) is a London-based biopharmaceutical company that develops and markets therapies for treating patients suffering from respiratory diseases. Incorporated in 2005, the company is committed to improving the lives of many by offering innovative drugs. While we acknowledge the potential of VRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
3 hours ago
- Yahoo
Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch
Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, with an unchanged 'Buy' rating. This was after the successful launch of the COPD treatment Ohtuvayre, which has witnessed strong sales growth. During the first quarter, Ohtuvayre delivered $71 million in sales, reflecting an increase of nearly 90% from the previously reported 37 million in the last quarter. Verona Pharma plc (NASDAQ:VRNA) continues to capitalize on this growing demand, with peak sales projections between $3 billion and $5 billion. As the numbers suggest, this is anything but ordinary. The optimism surrounding the company's profitability in the second quarter is just the cherry on top. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Some believe that Verona Pharma plc (NASDAQ:VRNA) is heading north to be the next big franchise. With its potential, Wall Street anticipates the giant to achieve $1 billion in sales by 2028, driven by its safety profile, global expansion, robust patent protection, and an underserved market of 398 million people with COPD. Verona Pharma plc (NASDAQ:VRNA) is a London-based biopharmaceutical company that develops and markets therapies for treating patients suffering from respiratory diseases. Incorporated in 2005, the company is committed to improving the lives of many by offering innovative drugs. While we acknowledge the potential of VRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
